Start Your Journey Today <\/a>\n <\/div>\n<\/div>\n<\/p>\n
Case Example of AI Success in Oncology: Ontada and OncoLens<\/h2>\n
Companies like Ontada and OncoLens demonstrate the effective use of AI to improve patient outcomes through streamlined trial matching processes. Ontada, a McKesson company, has transformed over 150 million unstructured oncology documents into actionable data via Microsoft\u2019s Azure AI technologies. With a reported fourfold improvement in access to critical data across various cancer types, Ontada shows how AI can speed up drug development and enhance oncological research.<\/p>\n
OncoLens supports over 950 community cancer centers, using Natural Language Processing (NLP) and machine learning to improve patient care. Their AI-driven clinical trial matching engine enables real-time identification of suitable trials for patients. This platform not only increases patient referrals but also enhances overall physician engagement, with reports of improvements reaching 50%. Such advancements indicate a movement toward a more data-driven approach that effectively utilizes real-world evidence.<\/p>\n
Overcoming After-Hours Challenges with AI Solutions<\/h2>\n
After-hours access to clinical trials can significantly improve care. Clinics often receive inquiries from potential participants at unconventional times when staff may not be available. AI systems can fill this gap by providing automated responses based on predefined datasets that inform patients about available options without requiring real-time human interaction.<\/p>\n
By implementing AI-driven systems, administrators can ensure continuity of care. These technologies integrated into existing workflows allow for 24\/7 patient engagement, enabling individuals seeking information about clinical trials to receive timely responses. For example, advanced chatbots and digital assistants can provide information on eligibility criteria, available trials, and subsequent steps by analyzing patient queries.<\/p>\n
Additionally, the efficient matching provided by AI can lead to significant cost savings for healthcare providers. Streamlining workflow processes helps reduce manual labor related to trial matching, minimizes delays in enrollment, and potentially increases revenue from pharmaceutical partnerships.<\/p>\n
AI and Workflow Automation in Clinical Trial Matching<\/h2>\nEnhancing Workflow Efficiency<\/h3>\n
The use of AI-driven automation tools allows for improvements in annual reporting and accreditation processes. For instance, OncoLens reported that oncology practices using their platform have saved 65% to 90% of the time on essential accreditation and reporting activities. This efficiency minimizes the time spent on data aggregation, enabling oncologists to devote more resources to patient care.<\/p>\n
Improved Patient Identification<\/h3>\n
AI significantly enhances the accuracy of patient identification. By processing large amounts of unstructured data, such as electronic health records (EHRs), lab results, and patient histories, AI can identify eligible trial candidates more effectively than traditional methods. AI-driven identification achieves an accuracy rate of 85% to 90%, representing a considerable advancement over manual processes. This improvement not only enhances matching accuracy but also ensures that all eligible candidates are considered for trial participation.<\/p>\n
Streamlining Multidisciplinary Collaboration<\/h3>\n
Effective communication and collaboration are critical in oncology care, involving numerous stakeholders. AI platforms like OncoLens facilitate real-time data sharing and team engagement. This functionality enables physicians from various specialties to come together quickly, discuss patient cases, and provide input on treatment options, including those available through clinical trials.<\/p>\n
Real-time discussions allow care teams to make more informed decisions based on current data, ultimately improving the quality of patient care. The platform encourages participation from various specialists, overcoming logistical challenges that typically complicate trial referrals.<\/p>\n
<\/p>\n